Discounted Cash Flow
ANI Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $128.6m | $3.9m | $22.9m | 3.1% | $0.34 |
| 2017 | $176.8m (37.5%) | $-1.1m (-127.4%) | $29.1m (26.8%) | -0.6% (-119.9%) | $-0.09 (-126.5%) |
| 2018 | $201.6m (14.0%) | $15.5m (1540.0%) | $61.3m (111.1%) | 7.7% (1363.3%) | $1.31 (1555.6%) |
| 2019 | $206.5m (2.5%) | $6.1m (-60.7%) | $39.0m (-36.4%) | 3.0% (-61.6%) | $0.51 (-61.1%) |
| 2020 | $208.5m (0.9%) | $-22.5m (-470.0%) | $9.1m (-76.6%) | -10.8% (-466.6%) | $-1.88 (-468.6%) |
| 2021 | $216.1m (3.7%) | $-42.6m (-88.9%) | $765.0k (-91.6%) | -19.7% (-82.2%) | $-3.40 (-80.9%) |
| 2022 | $316.4m (46.4%) | $-47.9m (-12.4%) | $-40.1m (-5339.1%) | -15.1% (23.2%) | $-3.05 (10.3%) |
| 2023 | $486.8m (53.9%) | $18.8m (139.2%) | $110.1m (374.7%) | 3.9% (125.5%) | $0.86 (128.2%) |
| 2024 | $614.4m (26.2%) | $-18.5m (-198.6%) | $47.8m (-56.6%) | -3.0% (-178.2%) | $-1.04 (-220.9%) |
| 2025 | $883.4m (43.8%) | $78.3m (522.9%) | $171.4m (258.7%) | 8.9% (394.2%) | $3.50 (436.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.